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     HTLV1 is the first detected retrovirus causing disease in human. The physiopathology of HTLV1 
related diseases was mainly linked with its Tax protein characteristics. Use of mutant Tax proteins 
accompanied by immune regulator drugs could help treating HTLV1 associated myelopathy patients 
as a modulator of potent immune response against this viral protein. Since Tax protein is not 
commercially available, production of recombinant Tax protein was targeted for this study. Coding 
sequence of Tax protein (containing R222K mutation) in the pcDNA3.1(+) was digested with BamHI 
and XhoI restriction enzymes, and then removed and inserted into the expression vector pET32a(+) 
within the same cutting sites and cloned into E.coli DH5α. Recombinant vector was confirmed with 
enzymatic digestion, colony PCR, and sequencing of cloned gene. E.coli Rosetta (DE3) was 
transformed with the recombinant plasmid and the expression was induced. The expression of protein 
was assayed with SDS-PAGE and western blot using monoclonal antibodies against Tax and 5His 
epitope. Finally, antigenic characteristic of the recombinant protein was evaluated by western blotting 
against patient sera. Presence of Tax protein band in the SDS-PAGE and western blot was confirmed. 
Western blotting of the recombinant protein with patient sera showed the band related to Tax protein. 
The recombinant protein is well produced and could be detected by patients' sera, making it eligible 
to be used as a recombinant viral antigen for future purposes.  
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INTRODUCTION  
     HTLV1 (Human T Lymphotropic Virus 
Type 1) is the first human retrovirus 
discovered in 1980 [1]. Morphologically, 
HTLV1 is type C of delta virus category 
which is similar to lentiviruses (Human 
Immunodeficiency Viruses), with ability to 
long-term infection of human cells. HTLV1 is 
able to transform primary human T cells and 
creates immortal T cell’s in vitro [2]. At first, 
pathological outcome of this virus, i.e. 
leukemia (lymphoid cancer) of T cells in adult 
(Adult T Cell Leukemia (ATL)) was detected 
three years before the discovery of the virus 
[3]. Accordingly, second disease raised by this 
virus was diagnosed which is a chronic 
nervous disease of lower limbs (TSP) 
(Tropical Spastic Paraparesis) [4], that was 
later related to HTLV1  (HTLV1 Associated 
Myelopathy (HAM)) as myelopathy [5]. 
HTLV1 as a disease is not prevalent and this 
virus is not the same in every part of the 
world. Just some regions are considered as 
endemic centers [6]. This virus is more 
prevalent in the Caribbean countries, south of 
Japan, Southern America and recently it is 
reported in northeastern Iran and Mashhad, so 
that the infection of this virus is reported in 
some regions of Khorassan Province up to 3% 
[7, 8]. As one of the most common 
transmission routes is via breast feeding, 
safety measures like avoiding breast feeding 
of newborns by infected mothers can prevent 
up to 97% of such cases [9]. Transmission by 
sex can also be highly prevented by using 
physical prophylaxis. Systematic screening of 
the donated bloods in blood transfusion 
services is another preventive measure which 
has been applied in several countries since 
1986 and in high prevalent province of 
Khorassan in Iran for the past few years [8]. 
By applying these methods, the spread of the 
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disease could be very well controlled, without 
need for developing any vaccine. However, 
neither preventive immunization approaches, 
nor any of the above mentioned methods can 
help 15-20 million people who are already 
infected and 5-10% of whom that may develop 
serious outcomes in the future. So, in the last 
few years some attempts have been made to 
develop drug therapies or therapeutic vaccines 
for HTLV1 [10-13]. The physiopathology of 
HTLV1 related diseases is tightly mixed with 
extra ordinary properties of its Tax protein that 
has an important role in virus production and 
pathogenesis of HTLV1 related diseases [14]. 
In fact, Tax is the primary agent for oncogenic 
role of HTLV1, which leads to ATL, and 
strong immune response to this protein is the 
prime suspect for HAM-TSP pathogenesis. In 
other words, this protein is important in the 
life cycle and biology of the virus. It also is 
required for replication and to change the 
structure of host cell to meet the needs of the 
virus [10, 15, 16]. On the other hand, Tax is 
also one of the most conserved parts of this 
virus. This characteristic is an advantage for a 
vaccine candidate, because a conserved 
antigen could work for all subtypes of the 
pathogen for which the vaccine is designed 
against. For this purpose, any attempt to use it 
in a vaccination design should be after 
inactivation of this protein using changes 
happening in its coding sequence. For this 
project, in order to express protein, Tax cDNA 
with reported R222K mutation was used. This 
mutation is used to decrease Tax intervention 
in cell signaling pathway. In this mutant 
protein, lysine amino acid has replaced 
arginine [17]. It is reported that ubiquitination 
of Tax plays an important controlling role in 
the activation of NFKB pathway [18,19]. 
Therefore, lysin instead of arginine in this 
region may cause a ubiquitination site for Tax, 
and dramatically decrease activation of NFKB 
[17]. 
     Use of different types of mutant Tax 
proteins in association with immune-
modulator substances could act as strong 
immune-modulator for designing the vaccine. 
These harmful immune responses cause 
HAM-TSP disease and modulating their 
responses is a promising way for healing 
people affected by this disease [20, 21]. For 
this reason, the present study has sought the 
production of new Tax protein composition 
with the mentioned characteristics.  
 
MATERIALS AND METHODS 
     In order to clone recombinant Tax gene, its 
coding sequence, including 1062 base pairs 
and containing R222K mutation, was cut out 
of pcDNA3.1(+)-Tax Eukaryotic vector using 
BamHI and XhoI restriction enzymes, and was 
then inserted into the prokaryotic expression 
vector pET32a(+) within the same cutting sites 
and cloned into E.coli DH5α. Recombinant 
vector was confirmed with enzymatic 
digestion, colony PCR and sequencing of the 
cloned gene (Takapou zist Co.). For colony 
PCR the following primer pair was used:  
* forward Primer: T7 promoter  
5´ - TAA TAC GAC TCA CTA TAG GG-3  ́
*Reverse primer  
5´ - TGT CTC GAG GAC TTC TGT TTC 
AC-3´    
Sequence of Tax in vector pET32a(+) was 
confirmed and Plasmid pcDNA3.1-Tax was 
used as positive control and plasmid 
pET32a(+) as negative control in colony PCR. 
Recombinant vector after confirmation for 
accuracy of cloning was transferred to the 
expressing host E.coli Rosetta (DE3) and 
expression was induced. After optimizing the 
effective conditions, the recombinant protein 
was expressed in optimal condition of IPTG 
1mM, 30   C temperature, 2xYT+1%Glc 
culture and 6 hours incubation after induction 
in form of fusion with His-tag. The expression 
of the recombinant protein was assayed with 
SDS-PAGE and Western blot analysis. 
In order to confirm Tax protein and its 
expression with His-tag fusion, Western blot is 
performed with mouse anti Tax monoclonal 
Ab produced (Abcam) with a dilution of 1/200 
and penta anti-His monoclonal Ab, (Sigma) in 
a dilution of 1/2000. The antigenisity of Tax 
was evaluated by western blot using sera of 
HTLV1 infected people and was compared 
with uninfected people. For this study, serum 
samples for patients as well as for healthy 
people were prepared with dilution of 1/500. 
The sera were absorbed with bacterial lysate to 
remove non-specific antibodies against E.coli. 
Fifteen different sera samples were used for 
this analysis, including 10 patients (infected or 
HAM-TSP) and 5 control samples. . In order 
to achieve best result in the process of western 
blot, method optimization was performed 
through changing in antibody concentration 
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 and other effective factors.  
 
RESULTS 
     The result related to colony PCR and 
vector pET32a (+)-Tax recombinant vector is 
demonstrated in Figure 1. Development of 
band 1600 base pair in columns 1 to 14 relates 
to the cloned Tax gene in vector 
pET32a(+).The SDS PAGE analysis shows 
development of 50 kDa protein band after 
induction comparing with sample before 
induction of which suggests successful 
expression of Tax protein (Figure 2). A 
protein band was observed in the western blot 
with mouse anti Tax monoclonal Ab and penta 
anti-His monoclonal Ab, at almost 55 kDa 
(Figure 3). A similar band was observed after 
western blotting using patients' sera (Figure 4). 
The result of western blot with serum of one 
of people in the control group is also shown in 




Figure 1. Colony PCR test confirms tax insertion into pET32a(+). Columns1-14: PCR product using transformed colonies. 
Column15: marker (Fermentas SM1123). Column16: PCR product using pcDNA3.1-tax as positive control. Column17: 










Figure 2. SDS-PAGE analysis for expression of recombinant protein in Rosetta (DE3) transformed with pET32a-tax. 
Column1: marker (Fermentas SM0431). Column2: before induction sample with IPTG. Column3: after induction sample 
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Figure 3. Analysis of recombinant Tax protein expression with anti-Tax monoclonal Ab and Penta anti-His monoclonal Ab. 
Column1: marker (Fermentas SM1811). Column2: before induction sample blotted with anti-Tax monoclonal Ab. Column3: 
after induction sample blotted with anti-Tax monoclonal Ab. Column4: before induction sample blotted with Penta anti-His 
monoclonal Ab. Column5: after induction sample blotted with Penta anti-His monoclonal Ab 
 
 
Figure 4. Evaluating of antigenic characteristic in recombinant Tax protein by western blotting against patient serum. 
Column1: marker (Fermentas SM1811). Columns2-11: after induction sample blotted with HAM-TSP patient 
 
 
Figure 5. Evaluating of antigenic characteristic in recombinant Tax protein by western blotting against healthy people as 
control. Column1: marker (Fermentas SM1811). Columns2-6:  after induction sample blotted with control group 
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     HTLV1 virus is a real health problem in 
some parts of Iran and up to 3% of general 
population is infected by this virus in some 
regions of Khorasan Province. All these 
infected people fear the disappointing possible 
outcomes of their infection and are looking for 
a helpful therapy. On the other hand, 
preventive measures for blocking the 
transmission of this virus don’t help those who 
are infected with this virus and between 5 to 
10 percent of these people will show 
progressive diseases in their life. Therapeutic 
vaccine might be one of the effective methods 
for treating such patients. Many efforts have 
been performed during recent years for 
treatment of HTLV1 using medicine and 
therapeutic vaccine [14]. Tax is the immune-
dominant protein for CTL response in 
HTLV1, while it is one of the most conserved 
parts of this virus. These characteristics are 
considered as important advantage for 
producing a candidate vaccine [14, 22]. 
However, most worrisome concern about Tax 
is its intracellular adverse effects; for this 
reason, any effort to use it for producing 
vaccine shall be done after inactivation of 
harmful effects of this protein using change in 
its genome. Therefore, production of 
recombinant Tax protein with mutation of 
R222K was performed [23-26]. Since cloning 
process is implemented through sub cloning 
but no PCR, thus the gene was not prone to 
adverse effects of PCR process (such as 
appearance of point mutation), accordingly, 
mistake in cloning seems absolutely 
impossible. However, for confirmation of 
cloning accuracy, colony PCR confirms Tax in 
vector pET32a(+). Whereas Forward primer 
(T7) is selected from sequence of vector, 
cloned Tax gene must be longer 
(approximately 500 bp) than Tax gene in 
positive control, therefore, according to Figure 
1, after electrophoresis of PCR product in all 
selected colonies, band 1600 of base pair was 
observed in agarose gel comparing to the 
approximately band of 1100 base pair in 
sample of positive control; although no PCR 
product was achieved from pET32a(+) PCR. 
In this manner, after ensuring correct cloning 
and expression vector; effective condition of 
expression process such as inducer 
concentration, incubation time after induction, 
expression temperature, bacterial media 
culture and expression host have been 
considered. It is expected that Tax protein be 
expressed with 353 amino acid and molecular 
weight of 40 kDa. The leader polypeptide with 
170 amino acid adds about 15 to 18 kDa to 
molecular weight of recombinant protein. So, 
in case of successful expression, a 55 kDa 
band will be observed. However, recombinant 
Tax protein is observed with approximate 
weight of 50 kDa in SDS-PAGE gel (Figure 
2). Such observation may be due to error in 
measuring with the used marker in SDS-
PAGE comparing with used marker in western 
blot (regarding usage of different markers in 
each technique).  
     Bioinformatics studies suggest that Tax 
gene has 44 rare codones, including 5 codones 
related to Arginine, 5 codones coding 
isoleucine, 10 codones of leucine and 24 
codones coding proline, which are very rarely 
used in conventional E.coli expression system 
(http://nihserver.mbi.uda.edu/PACC). It may 
reduce expression level of Tax in E.coli. 
Rosetta (DE3) carries plasmid which encodes 
tRNA related to rare codones in eukaryotes. 
Consequently, expression of Tax protein is 
increased in this host [27-29].  
Through study on effective factors of protein 
expression, it was realized that decreasing 
temperature from 37 to 30  C after induction 
with IPTG may cause increase in expression 
of recombinant Tax protein. Decreasing 
temperature may provide suitable folding 
condition for the protein, so stability of 
soluble protein and finally protein yield in 
soluble form could be increased [27]. Since 
maximum activity of cellular protoases is 
happens in 37  C, therefore, if Tax protein 
expression is optimal within this temperature, 
effect of proteases may cause protein 
decomposition and prevents determination of 
expression. Therefore, decrease in temperature 
could be effective in successful protein 
expression through prevention of cellular 
proteases activation.    
     For optimization of Tax protein expression, 
1% glucose in 2xYT medium, significantly 
increased expression comparing with the 
medium without it. The better expression of 
Tax protein with glucose could be attributed to 
suppressing effect of glucose for leak 
expression of T7 RNA polymerase before 
induction with IPTG [30-35]. Western blot of 
Tax protein with exclusive monoclonal 
antibody against Tax epitopes demonstrated a 
55kDa band which is in concordance with the 
expected molecular weight (Figure 3). In order 
to confirm expression of Tax protein with 
histidine tag, western blot of expressed 
recombinant protein was performed with 
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specific antibody against this tag. Achieved 
results of blotting have shown one 55kDa 
band corresponding to the expected Tax 
protein as well as a 35kDa band (Figure 3). It 
seems that this 35 kDa band is related to a 
protein of E.coli that was detected non-
especially by Penta anti-His monoclonal due 
to its histidine content.  
     Since final goal of this study had been to 
use this protein in vaccine design, presence of 
antibody against Tax in serum of patients 
comparing with healthy people (control group) 
was evaluated by western blot to confirm 
antigenic characteristic of Tax protein. It is 
well documented that antibodies against Tax 
protein exist in most patients (who have 
antibody against antigens of HTLV1). 
Existence of 55 kDa band in sample after 
induction according to Figure 4, suggests the 
antibodies of the patients can react with our 
expressed Tax protein. Whereas blotting with 
patient’s serum has had always background 
due to non special antibodies against E.coli, 
the results of before and after induction must 
be compared for presence or absence of the 
desired band. This band is not observed in 
before induced samples as indicated in Figure 
4.  
     After optimizing expression condition, it 
was observed that the expression host is the 
most effective in expression of Tax 
recombinant protein. Actually, Rosetta (DE3) 
having plasmid which codes tRNAs of some 
rare codones in E.coli, considerably influenced 
on expression of recombinant Tax.  
Study of western blot for recombinant protein 
using serum of patients suggests the expressed 
protein is well reactive to patients' sera. 
Measuring the amount of these antibodies has 
prognostic value for such patients. However, 
low level expression of Tax protein in this 
study is considered as weak point, limiting it 
for using it as vaccine. Therefore, further 
optimizing the expression of this protein is 
suggested for next steps.  
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